Interferon in polycythemia vera
Brian Edwards
Cancer-associated thrombosis
Tarik Hodžić
Gene therapy for hemoglobinopathies: access and long-term follow-up
Marie Berger
Managing CLL after BTK and BCL-2 inhibitors
Julien David
Myeloproliferative neoplasms: diagnosis and risk assessment
Clara Vázquez
Bleeding, thrombosis and platelets: diagnosis and risk assessment
Ece Şimşek
Gene and cellular therapy: controversies and case discussion
Elena Matei
Chronic lymphocytic leukemia: first-line treatment
Birgit Köhler
Myeloproliferative neoplasms: long-term follow-up
Stefan Krause
Bleeding, thrombosis and platelets: long-term follow-up
Daniel Brown
Gene and cellular therapy: emerging therapies
Andreas Fuchs
Chronic lymphocytic leukemia: first-line treatment
Nuno Oliveira
Long-term outcomes of T-cell ALL treated with inotuzumab ozogamicin: a Nordic registry study of 58 patients
Mathilde Lambert
Menin-kmt2a dependency predicts outcome in NPM1-mutated AML
Julia Martin
Measurable residual disease by flow cytometry predicts outcome in relapsed or refractory FLT3-mutated AML
Pavel Procházka
Complex karyotype predicts outcome in treatment-naive CLL
Rachel Campbell
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective spanish study
Julia Thomas
Ascavinib plus dasatinib in CML after two or more tyrosine kinase inhibitors: phase 1b/2 results of the ZENITH-4 trial
Bruno Oliveira
Corvalimab versus blinatumomab in T-cell ALL (VALOR-2): a randomized phase 3 trial
David Miller
Quelcitamab versus venetoclax and azacitidine in AML in first complete remission (NORDLYS-5): a phase 3 trial
Stefanie Kaiser
Ravotuzumab vedotin plus decitabine in relapsed or refractory FLT3-mutated AML: phase 1 results of the VIKING-4 trial
Pietro Moretti
Single-cell profiling reveals Richter transformation in chronic lymphocytic leukemia (CLL)
Fabio Esposito
Ascavinib versus dasatinib in chronic-phase CML in deep molecular response (ECLIPSE-9): a randomized phase 2 trial
Marie Vogel
Prognostic value of fetal hemoglobin induction in patients receiving CD19-directed CAR T-cell therapy: results from VALOR-1
Lei Li
Health-related quality of life in T-cell ALL: a prospective dutch study
Moritz Lehmann
Multi-omic characterization of metabolic rewiring under BCL-2 inhibition in older adults with secondary AML
Frank Hofmann
Efficacy and safety of quelcitamab in older adults with secondary AML: primary analysis of the phase 3 BEACON-5 study
Cristina Rizzo
Nelbrutinib plus acalabrutinib in CLL with del(17p) or TP53 mutation: phase 3 results of the SAGA-5 trial
Maya Shapiro
Ravelinib plus imatinib in CML after two or more tyrosine kinase inhibitors: randomized phase 2 results of the VALOR-6 trial
Hannah Brown
Treatment patterns and survival in patients receiving CD19-directed CAR T-cell therapy: real-world data from the multinational cell therapy registry
Anne Richard
Multi-omic characterization of steroid resistance pathways in adolescents and young adults with ALL
Dimitrios Christodoulou
Ravotuzumab vedotin versus venetoclax and azacitidine in older adults with secondary AML (PRISM-3): a phase 3 trial
John Wright
Measurable residual disease by flow cytometry predicts outcome in AML in first complete remission
Agnieszka Piotrowski
Pirvabrutinib versus venetoclax and obinutuzumab in older patients with CLL and comorbidities (POLARIS-3): a randomized phase 2 trial
Martin Möller
Real-world effectiveness of orvematinib in newly diagnosed chronic-phase CML: a multicenter international cohort
Edward Murray
Zelvudocel plus lymphodepletion with fludarabine and cyclophosphamide in patients with sickle cell disease treated with gene editing: phase 1 results of the ALTITUDE-7 trial
Martijn Smits
Efficacy and safety of ibrexitamab in relapsed B-cell precursor ALL: primary analysis of the phase 2 ALTITUDE-2 study
Roberta Rossi
Health-related quality of life in adults with newly diagnosed AML receiving intensive induction: a prospective european study
Sanjay Nair
Real-world effectiveness of concivumab in people with severe hemophilia A: a multicenter dutch cohort
Elisa Ferri
Health-related quality of life in chronic-phase CML in deep molecular response: a prospective italian study
Bo Zhu
Early molecular response at 3 months predicts outcome in chronic-phase CML in deep molecular response
Chen Li
Car t expansion kinetics predicts outcome in patients receiving CD19-directed CAR T-cell therapy
Ingrid Bos
Health-related quality of life in children with high-risk B-cell ALL: a prospective german study
Youssef Saleh
Flt3-itd allelic ratio predicts outcome in older adults with secondary AML
Sem Dekker
Long-term outcomes of cancer-associated venous thromboembolism treated with thrombopoietin receptor agonists: a European registry study of 2105 patients
Felix Kaiser
Single-cell profiling reveals treatment-free remission biology in chronic myeloid leukemia (CML)
Thomas Mercier
Multi-omic characterization of treatment-free remission biology in CML after two or more tyrosine kinase inhibitors
Pavel Veselý
Real-world effectiveness of lovotigene autotemcel in patients receiving CD19-directed CAR T-cell therapy: a multicenter german cohort
Christina Koch
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Ana Nikolić, Uri Barak, Brian Edwards
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Wei Yang, Brian Scott, Karim Aziz
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Rebecca Mitchell, Johanna Peters, Emre Demir
Survivorship care after hematologic cancer
Marie Winkler
Iron deficiency without anemia
Fatma Özdemir
Large language models in clinical hematology
Neda Moradi
Transplantation in MDS: timing and conditioning
Uri Barak
Supportive care and quality of life: controversies and case discussion
Fang Sun
Red cell disorders and hemoglobinopathies: first-line treatment
Julien Lefebvre
Novel technologies and AI: emerging therapies
Josip Vuković
Myelodysplastic syndromes: emerging therapies
Jelena Jurić
Supportive care and quality of life: managing relapse
Klaus Fuchs
Red cell disorders and hemoglobinopathies: emerging therapies
Julie Garcia
Novel technologies and AI: diagnosis and risk assessment
Lena Pettersson
Myelodysplastic syndromes: long-term follow-up
Victoria Jackson
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Carlos Hernández
Plenary lecture: Clonal hematopoiesis, aging and disease
Markus Keller